Powerful Small Molecule Platform
Predictive Companion Diagnostic
Targeted Alpha Therapy
Scientific Board of Advisors
University of Pennsylvania study demonstrates [
F]FTT is a biomarker of ovarian cancer response to PARP Inhibitor Treatment
University of Pennsylvania publishes study of efficacy of
demonstrating complete tumor response in 81.8% of high-risk neuroblastoma tumors in mice with tolerable hematologic and marrow toxicity.
Partner with us
Learn how you can be a part of the paradigm-changing solution that will change the way we treat cancer.